EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase I)Open Access · CC BY-NC-ND 4.0

Neoadjuvant treatment of IBI310 plus sintilimab in locally advanced MSI-H/dMMR colon cancer: A randomized phase 1b study

Feng Wang, Gong Chen, Meng Qiu, Jinfeng Ma, Xianwei Mo, Haiyi Liu, Yongqiang Li, Peirong Ding, Xiangbin Wan, Yingbin Hu, Xiwen Huang, Weiqin Jiang und 33 weitere

Cancer Cell · 2025-10 · 43 (10) · 1958-1967.e2

DOI: 10.1016/j.ccell.2025.09.004 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Cancer Cell, 2025-10. Verfasst von Feng Wang und 44 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical …. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Neoadjuvant Therapy, Colonic Neoplasms, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China, Sun Yat-sen University, Sun Yat-sen University Cancer Center.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedNeoadjuvant TherapyColonic NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsHumansMaleFemaleMiddle AgedAgedMicrosatellite InstabilityDNA Mismatch RepairAdultImmune Checkpoint Inhibitors

Stichwörter der Autor:innen

anti-CLTA-4anti-PD-1colon cancerimmunotherapymicrosatellite instability-highmismatch repair-deficient

Substanzen

Antibodies, Monoclonal, HumanizedsintilimabImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University, Guangzhou, China;…
  • West China Hospital of Sichuan University, Chengdu, China.
  • Shanxi Cancer Hospital, Taiyuan, China.
  • Guangxi Medical University Cancer Hospital, Nanning, China.
  • Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University, Guangzhou, China.
  • Henan Cancer Hospital, Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China.

Förderung

  • National Natural Science Foundation of China
  • Sun Yat-sen University
  • Sun Yat-sen University Cancer Center
  • Innovent Biologics
  • Beijing Xisike Clinical Oncology Research Foundation

Zitieren

APA

Wang, F., Chen, G., Qiu, M., Ma, J., Mo, X., Liu, H., Li, Y., Ding, P., Wan, X., Hu, Y., Huang, X., Jiang, W., Wu, X., Luo, J., Zhou, Y., Li, L., Sun, Y., Wang, Q., Wang, N., …, & Xu, R. H. (2025). Neoadjuvant treatment of IBI310 plus sintilimab in locally advanced MSI-H/dMMR colon cancer: A randomized phase 1b study. Cancer Cell, 43(10), 1958-1967.e2. https://doi.org/10.1016/j.ccell.2025.09.004

Vancouver

Wang F, Chen G, Qiu M, Ma J, Mo X, Liu H, et al. Neoadjuvant treatment of IBI310 plus sintilimab in locally advanced MSI-H/dMMR colon cancer: A randomized phase 1b study. Cancer Cell. 2025;43(10):1958-1967.e2. doi:10.1016/j.ccell.2025.09.004

BibTeX
@article{Wang2025,
  author = {Wang, Feng and Chen, Gong and Qiu, Meng and Ma, Jinfeng and Mo, Xianwei and Liu, Haiyi and Li, Yongqiang and Ding, Peirong and Wan, Xiangbin and Hu, Yingbin and Huang, Xiwen and Jiang, Weiqin and Wu, Xiaojun and Luo, Jia and Zhou, Yanbing and Li, Leping and Sun, Yanlai and Wang, Quan and Wang, Nanya and Jiang, Wu and Yuan, Weitang and Li, Liren and Liu, Linlin and Yuan, Xianglin and Wang, Guihua and Song, Zhangfa and Liu, Heli and Ge, Jie and Wang, Yaxu and Zhao, Peng and Li, Taiyuan and You, Jun and Tang, Jianqiang and Du, Xiaobo and Lin, Junzhong and Zhang, Rongxin and Fu, Zan and Xu, Jianmin and Zhong, Haijun and Kang, Liang and Deng, Yanhong and Lu, Xiaoxiao and Guo, Qun and Zhou, Hui and Xu, Rui-Hua},
  title = {Neoadjuvant treatment of IBI310 plus sintilimab in locally advanced MSI-H/dMMR colon cancer: A randomized phase 1b study},
  journal = {Cancer Cell},
  year = {2025},
  volume = {43},
  number = {10},
  pages = {1958--1967.e2},
  doi = {10.1016/j.ccell.2025.09.004}
}
Kostenlos starten →